[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.197.114. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
March 1987

Whither the ANA?

Author Affiliations

From the Department of Dermatology, Harvard Medical School, Boston (Dr E. A. Lerner), and the Section of Molecular Neurobiology, Yale University School of Medicine, New Haven, Conn (Dr M. R. Lerner). Dr E. A. Lerner is presently with the Massachusetts General Hospital, Boston.

Arch Dermatol. 1987;123(3):358-362. doi:10.1001/archderm.1987.01660270096023
Abstract

Plasma cells or B cells of patients with autoimmune diseases produce antibodies directed against their own tissues. Over the past 40 years, both serendipity and the development of new techniques have led to a variety of serologic tests for the detection of such antibodies. An objective of many investigators has been to determine the specificity of these antibodies in order to delineate subsets of autoimmune diseases (Table 1). The purpose of this editorial is to trace the development of some of the techniques, their applications, and problems. It will become apparent that advancing technology does not necessarily lead to a simplified picture with respect to antibody specificity and disease states.

The lupus erythematosus (LE) cell test was the first serologic method for detecting systemic LE (SLE). Its origin dates from 1945, when Hargraves, from the Mayo Clinic, Rochester, Minn, visited Schleicher and Sharp at Minneapolis General Hospital and learned a

First Page Preview View Large
First page PDF preview
First page PDF preview
×